<?xml version="1.0" encoding="UTF-8"?><?xml-stylesheet href="https://www.accessdata.fda.gov/spl/stylesheet/spl.xsl" type="text/xsl"?>
<document xmlns="urn:hl7-org:v3" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="urn:hl7-org:v3 https://www.accessdata.fda.gov/spl/schema/spl.xsd">
   <id root="6fb899dd-d30f-4391-9c79-cf79d4aec06f"/>
   <code code="34391-3" codeSystem="2.16.840.1.113883.6.1" displayName="HUMAN PRESCRIPTION DRUG LABEL"/>
   <title>
      <content styleCode="bold">Fluocinonide Cream USP, 0.05% </content>
      <br/>
      <content styleCode="bold">Fluocinonide Cream USP, 0.05% (Emulsified Base) </content>
      <br/>
      <content styleCode="bold">Fluocinonide Gel USP, 0.05% </content>
      <br/>
      <content styleCode="bold">Fluocinonide Ointment USP, 0.05%</content>
   </title>
   <effectiveTime value="20250513"/>
   <setId root="80b72854-3fae-4cc7-bc41-2bdeb3e2cbe1"/>
   <versionNumber value="3"/>
   <author>
      <time/>
      <assignedEntity>
         <representedOrganization>
            <id extension="791119022" root="1.3.6.1.4.1.519.1"/>
            <name>Preferred Pharmaceuticals Inc.</name>
            <assignedEntity>
               <assignedOrganization>
                  <id extension="791119022" root="1.3.6.1.4.1.519.1"/>
                  <name>Preferred Pharmaceuticals Inc.</name>
                  <assignedEntity>
                     <assignedOrganization>
                        <id extension="791119022" root="1.3.6.1.4.1.519.1"/>
                        <name>Preferred Pharmaceuticals Inc.</name>
                     </assignedOrganization>
                     <performance>
                        <actDefinition>
                           <code code="C73607" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="RELABEL"/>
                           <product>
                              <manufacturedProduct classCode="MANU">
                                 <manufacturedMaterialKind>
                                    <code code="68788-8554" codeSystem="2.16.840.1.113883.6.69"/>
                                 </manufacturedMaterialKind>
                              </manufacturedProduct>
                           </product>
                        </actDefinition>
                     </performance>
                  </assignedEntity>
               </assignedOrganization>
            </assignedEntity>
         </representedOrganization>
      </assignedEntity>
   </author>
   <component>
      <structuredBody>
         <component>
            <section>
               <id root="8e5e906d-5a62-4fa3-9447-2a244bcf0126"/>
               <code code="48780-1" codeSystem="2.16.840.1.113883.6.1" displayName="SPL product data elements section"/>
               <effectiveTime value="20250513"/>
               <subject>
                  <manufacturedProduct>
                     <manufacturedProduct>
                        <code code="68788-8554" codeSystem="2.16.840.1.113883.6.69"/>
                        <name>Fluocinonide</name>
                        <formCode code="C42966" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="OINTMENT"/>
                        <asEntityWithGeneric>
                           <genericMedicine>
                              <name>Fluocinonide</name>
                           </genericMedicine>
                        </asEntityWithGeneric>
                        <asEquivalentEntity classCode="EQUIV">
                           <code code="C64637" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                           <definingMaterialKind>
                              <code code="51672-1264" codeSystem="2.16.840.1.113883.6.69"/>
                           </definingMaterialKind>
                        </asEquivalentEntity>
                        <ingredient classCode="ACTIB">
                           <quantity>
                              <numerator unit="mg" value="0.5"/>
                              <denominator unit="g" value="1"/>
                           </quantity>
                           <ingredientSubstance>
                              <code code="2W4A77YPAN" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>Fluocinonide</name>
                              <activeMoiety>
                                 <activeMoiety>
                                    <code code="2W4A77YPAN" codeSystem="2.16.840.1.113883.4.9"/>
                                    <name>Fluocinonide</name>
                                 </activeMoiety>
                              </activeMoiety>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="230OU9XXE4" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>glyceryl monostearate</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="8D08K3S51E" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>propylene carbonate</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="6DC9Q167V3" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>propylene glycol</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="4T6H12BN9U" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>petrolatum</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="7G1J5DA97F" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>white wax</name>
                           </ingredientSubstance>
                        </ingredient>
                        <asContent>
                           <quantity>
                              <numerator unit="g" value="60"/>
                              <denominator value="1"/>
                           </quantity>
                           <containerPackagedProduct>
                              <code/>
                              <formCode code="C42794" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="TUBE"/>
                              <asContent>
                                 <quantity>
                                    <numerator unit="1" value="1"/>
                                    <denominator value="1"/>
                                 </quantity>
                                 <containerPackagedProduct>
                                    <code code="68788-8554-6" codeSystem="2.16.840.1.113883.6.69"/>
                                    <formCode code="C43182" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="CARTON"/>
                                 </containerPackagedProduct>
                                 <subjectOf>
                                    <marketingAct>
                                       <code code="C53292" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                                       <statusCode code="active"/>
                                       <effectiveTime>
                                          <low value="20231120"/>
                                       </effectiveTime>
                                    </marketingAct>
                                 </subjectOf>
                              </asContent>
                           </containerPackagedProduct>
                           <subjectOf>
                              <characteristic classCode="OBS">
                                 <code code="SPLCMBPRDTP" codeSystem="2.16.840.1.113883.1.11.19255"/>
                                 <value code="C112160" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="Type 0: Not a Combination Product" xsi:type="CE"/>
                              </characteristic>
                           </subjectOf>
                        </asContent>
                     </manufacturedProduct>
                     <subjectOf>
                        <approval>
                           <id extension="ANDA075008" root="2.16.840.1.113883.3.150"/>
                           <code code="C73584" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="ANDA"/>
                           <author>
                              <territorialAuthority>
                                 <territory>
                                    <code code="USA" codeSystem="2.16.840.1.113883.5.28"/>
                                 </territory>
                              </territorialAuthority>
                           </author>
                        </approval>
                     </subjectOf>
                     <subjectOf>
                        <marketingAct>
                           <code code="C53292" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                           <statusCode code="active"/>
                           <effectiveTime>
                              <low value="20231120"/>
                           </effectiveTime>
                        </marketingAct>
                     </subjectOf>
                     <consumedIn>
                        <substanceAdministration>
                           <routeCode code="C38304" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="TOPICAL"/>
                        </substanceAdministration>
                     </consumedIn>
                  </manufacturedProduct>
               </subject>
            </section>
         </component>
         <component>
            <section ID="ID_806576b1-31a0-438b-93bc-d3c594325f38">
               <id root="d5973157-b763-4569-8ce9-39b518a9b960"/>
               <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
               <text>
                  <paragraph>
                     <content styleCode="bold">For External Use Only. Not For Ophthalmic Use.</content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold">Rx only</content>
                  </paragraph>
               </text>
               <effectiveTime value="20250513"/>
            </section>
         </component>
         <component>
            <section ID="DESCRIPTION">
               <id root="fec3c766-e727-4ad7-ad48-3ccffc4efe15"/>
               <code code="34089-3" codeSystem="2.16.840.1.113883.6.1" displayName="DESCRIPTION SECTION"/>
               <title>DESCRIPTION</title>
               <text>
                  <paragraph>Fluocinonide Cream USP, 0.05%, Fluocinonide Cream USP, 0.05% (Emulsified Base), Fluocinonide Gel USP, 0.05% and Fluocinonide Ointment USP, 0.05% are intended for topical administration. The active component in each is the corticosteroid fluocinonide, which is the 21-acetate ester of fluocinolone acetonide and has the chemical name pregna-1,4-diene-3,20-dione,21-(acetyloxy)-6,9-difluoro-11-hydroxy-16,17-[(1-methylethylidene)bis(oxy)]-,(6α,11β,16α)-. It has the following chemical structure:</paragraph>
                  <renderMultiMedia ID="id738" referencedObject="ID_1fce77b6-f33d-4ed1-bf95-0ddd26c0e219"/>
                  <paragraph>Fluocinonide Cream USP, 0.05% contains fluocinonide 0.5 mg/g in a specially formulated cream base consisting of citric acid, glycerin, 1,2,6-hexanetriol, polyethylene glycol-3350, polyethylene glycol-8000, propylene glycol and stearyl alcohol. This white cream vehicle is greaseless, non-staining, anhydrous and completely water miscible. The base provides emollient and hydrophylic properties.</paragraph>
                  <paragraph>Fluocinonide Cream USP, 0.05% (Emulsified Base) contains fluocinonide 0.5 mg/g in a water-washable aqueous emollient base of cetyl alcohol, citric acid (anhydrous), mineral oil, polysorbate 60, propylene glycol, purified water, sorbitan monostearate, stearyl alcohol and white petrolatum.</paragraph>
                  <paragraph>Fluocinonide Gel USP, 0.05% contains fluocinonide 0.5 mg/g in a specially formulated gel base consisting of carbomer 940, edetate disodium, propyl gallate, propylene glycol, sodium hydroxide (to adjust pH) and purified water. This clear, colorless, thixotropic vehicle is greaseless, non-staining and completely water miscible.</paragraph>
                  <paragraph>Fluocinonide Ointment USP, 0.05% contains fluocinonide 0.5 mg/g in a specially formulated ointment base consisting of glyceryl monostearate, propylene carbonate, propylene glycol, white petrolatum and white wax. It provides the occlusive and emollient effects desirable in an ointment.</paragraph>
                  <paragraph>In the Fluocinonide Cream USP, 0.05%, Fluocinonide Gel USP, 0.05%, and Fluocinonide Ointment USP, 0.05% formulations, the active ingredient is totally in solution.</paragraph>
               </text>
               <effectiveTime value="20250513"/>
               <component>
                  <observationMedia ID="ID_1fce77b6-f33d-4ed1-bf95-0ddd26c0e219">
                     <text>Chemical Structure</text>
                     <value mediaType="image/jpeg" xsi:type="ED">
                        <reference value="fluocinonide-01.jpg"/>
                     </value>
                  </observationMedia>
               </component>
            </section>
         </component>
         <component>
            <section ID="CP">
               <id root="ffe4c2fb-6160-43a8-87c0-f83efc6c2370"/>
               <code code="34090-1" codeSystem="2.16.840.1.113883.6.1" displayName="CLINICAL PHARMACOLOGY SECTION"/>
               <title>CLINICAL PHARMACOLOGY</title>
               <text>
                  <paragraph>Topical corticosteroids share anti-inflammatory, anti-pruritic and vasoconstrictive actions.</paragraph>
                  <paragraph>The mechanism of anti-inflammatory activity of the topical corticosteroids is unclear. Various laboratory methods, including vasoconstrictor assays, are used to compare and predict potencies and/or clinical efficacies of the topical corticosteroids. There is some evidence to suggest that a recognizable correlation exists between vasoconstrictor potency and therapeutic efficacy in man.</paragraph>
               </text>
               <effectiveTime value="20250513"/>
               <component>
                  <section ID="ID_1cb4a612-18c6-40e0-90da-2f6a5ca60b9a">
                     <id root="292af5aa-25a0-4356-a2e9-6c3967381257"/>
                     <code code="43682-4" codeSystem="2.16.840.1.113883.6.1" displayName="PHARMACOKINETICS SECTION"/>
                     <title>Pharmacokinetics</title>
                     <text>
                        <paragraph>The extent of percutaneous absorption of topical corticosteroids is determined by many factors including the vehicle, the integrity of the epidermal barrier, and the use of occlusive dressings.</paragraph>
                        <paragraph>Topical corticosteroids can be absorbed from normal intact skin. Inflammation and/or other disease processes in the skin increase percutaneous absorption. Occlusive dressings substantially increase the percutaneous absorption of topical corticosteroids. Thus, occlusive dressings may be a valuable therapeutic adjunct for treatment of resistant dermatoses (see <content styleCode="bold">
                              <linkHtml href="#DA">DOSAGE AND ADMINISTRATION</linkHtml>
                           </content>).</paragraph>
                        <paragraph>Once absorbed through the skin, topical corticosteroids are handled through pharmacokinetic pathways similar to systemically administered corticosteroids. Corticosteroids are bound to plasma proteins in varying degrees. Corticosteroids are metabolized primarily in the liver and are then excreted by the kidneys. Some of the topical corticosteroids and their metabolites are also excreted into the bile.</paragraph>
                     </text>
                     <effectiveTime value="20250513"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="IU">
               <id root="23a245a1-574a-4b11-a835-c858a56faec0"/>
               <code code="34067-9" codeSystem="2.16.840.1.113883.6.1" displayName="INDICATIONS &amp; USAGE SECTION"/>
               <title>INDICATIONS AND USAGE</title>
               <text>
                  <paragraph>Fluocinonide Cream USP, 0.05%, Fluocinonide Cream USP, 0.05% (Emulsified Base), Fluocinonide Gel USP, 0.05% and Fluocinonide Ointment USP, 0.05% are indicated for the relief of the inflammatory and pruritic manifestations of corticosteroid-responsive dermatoses.</paragraph>
               </text>
               <effectiveTime value="20250513"/>
            </section>
         </component>
         <component>
            <section ID="CONTRAINDICATIONS">
               <id root="270d1843-f253-4130-baf9-a6d7b801c31b"/>
               <code code="34070-3" codeSystem="2.16.840.1.113883.6.1" displayName="CONTRAINDICATIONS SECTION"/>
               <title>CONTRAINDICATIONS</title>
               <text>
                  <paragraph>Topical corticosteroids are contraindicated in those patients with a history of hypersensitivity to any of the components of the preparations.</paragraph>
               </text>
               <effectiveTime value="20250513"/>
            </section>
         </component>
         <component>
            <section ID="PRECAUTIONS">
               <id root="4d8c6a37-173d-4e25-8062-9d3ea11c67c8"/>
               <code code="42232-9" codeSystem="2.16.840.1.113883.6.1" displayName="PRECAUTIONS SECTION"/>
               <title>PRECAUTIONS</title>
               <effectiveTime value="20250513"/>
               <component>
                  <section ID="ID_649c80d9-f1bc-47e7-9a1d-64b091fdad3b">
                     <id root="b2f44f20-2987-4760-bda4-b443de493127"/>
                     <code code="34072-9" codeSystem="2.16.840.1.113883.6.1" displayName="GENERAL PRECAUTIONS SECTION"/>
                     <title>General</title>
                     <text>
                        <paragraph>Systemic absorption of topical corticosteroids has produced reversible hypothalamic-pituitary-adrenal (HPA) axis suppression, manifestations of Cushing's syndrome, hyperglycemia, and glucosuria in some patients.</paragraph>
                        <paragraph>Conditions which augment systemic absorption include the application of the more potent steroids, use over large surface areas, prolonged use, and the addition of occlusive dressings.</paragraph>
                        <paragraph>Therefore, patients receiving a large dose of a potent topical steroid applied to a large surface area or under an occlusive dressing should be evaluated periodically for evidence of HPA axis suppression by using the urinary free cortisol and ACTH stimulation tests. If HPA axis suppression is noted, an attempt should be made to withdraw the drug, to reduce the frequency of application, or to substitute a less potent steroid.</paragraph>
                        <paragraph>Recovery of HPA axis function is generally prompt and complete upon discontinuation of the drug. Infrequently, signs and symptoms of steroid withdrawal may occur, requiring supplemental systemic corticosteroids.</paragraph>
                        <paragraph>Children may absorb proportionally larger amounts of topical corticosteroids and thus be more susceptible to systemic toxicity (see <content styleCode="bold">
                              <linkHtml href="#Pediatric">PRECAUTIONS - Pediatric Use</linkHtml>
                           </content>). If irritation develops, topical corticosteroids should be discontinued and appropriate therapy instituted.</paragraph>
                        <paragraph>As with any topical corticosteroid product, prolonged use may produce atrophy of the skin and subcutaneous tissues. When used on intertriginous or flexor areas, or on the face, this may occur even with short-term use.</paragraph>
                        <paragraph>In the presence of dermatological infections, the use of an appropriate antifungal or antibacterial agent should be instituted. If a favorable response does not occur promptly, the corticosteroid should be discontinued until the infection has been adequately controlled.</paragraph>
                     </text>
                     <effectiveTime value="20250513"/>
                  </section>
               </component>
               <component>
                  <section ID="ID_bf88306b-d04e-4d24-9098-07b62ded0c7c">
                     <id root="0162ed3c-a179-4a5c-a601-0cc843deaa34"/>
                     <code code="34076-0" codeSystem="2.16.840.1.113883.6.1" displayName="INFORMATION FOR PATIENTS SECTION"/>
                     <title>Information for the Patient</title>
                     <text>
                        <paragraph>Patients using topical corticosteroids should receive the following information and instructions:</paragraph>
                        <list listType="ordered">
                           <item>
                              <caption>1.</caption>This medication is to be used as directed by the physician. It is for external use only. Avoid contact with the eyes.</item>
                           <item>
                              <caption>2.</caption>Patients should be advised not to use this medication for any disorder other than for which it was prescribed.</item>
                           <item>
                              <caption>3.</caption>The treated skin area should not be bandaged or otherwise covered or wrapped as to be occlusive unless directed by the physician.</item>
                           <item>
                              <caption>4.</caption>Patients should report any signs of local adverse reactions, especially under occlusive dressing.</item>
                           <item>
                              <caption>5.</caption>Parents of pediatric patients should be advised not to use tight-fitting diapers or plastic pants on a child being treated in the diaper area, as these garments may constitute occlusive dressings.</item>
                        </list>
                     </text>
                     <effectiveTime value="20250513"/>
                  </section>
               </component>
               <component>
                  <section ID="ID_42683518-9ed6-4e6d-8c47-5dfe70da9d66">
                     <id root="47c53a7a-567b-4bc5-91ca-5dda0f699997"/>
                     <code code="34075-2" codeSystem="2.16.840.1.113883.6.1" displayName="LABORATORY TESTS SECTION"/>
                     <title>Laboratory Tests</title>
                     <text>
                        <paragraph>The following tests may be helpful in evaluating the HPA axis suppression:</paragraph>
                        <list listType="unordered">
                           <item>
                              <caption> </caption>Urinary free cortisol test</item>
                           <item>
                              <caption> </caption>ACTH stimulation test</item>
                        </list>
                     </text>
                     <effectiveTime value="20250513"/>
                  </section>
               </component>
               <component>
                  <section ID="ID_881727aa-fdfc-4652-aafb-f4ff58624e01">
                     <id root="a1fc63a0-755c-45b7-86ff-40400bbea9d3"/>
                     <code code="34083-6" codeSystem="2.16.840.1.113883.6.1" displayName="CARCINOGENESIS &amp; MUTAGENESIS &amp; IMPAIRMENT OF FERTILITY SECTION"/>
                     <title>Carcinogenesis, Mutagenesis, and Impairment of Fertility</title>
                     <text>
                        <paragraph>Long-term animal studies have not been performed to evaluate the carcinogenic potential or the effect on fertility of topical corticosteroids.</paragraph>
                        <paragraph>Studies to determine mutagenicity with prednisolone and hydrocortisone have revealed negative results.</paragraph>
                     </text>
                     <effectiveTime value="20250513"/>
                  </section>
               </component>
               <component>
                  <section ID="ID_9d570833-3400-4972-b11b-4874db618579">
                     <id root="98096daa-950a-4c0f-9427-0be09a93c0a0"/>
                     <code code="42228-7" codeSystem="2.16.840.1.113883.6.1" displayName="PREGNANCY SECTION"/>
                     <title>Pregnancy Category C</title>
                     <effectiveTime value="20250513"/>
                     <component>
                        <section ID="ID_e4740760-692f-4261-86f0-506438b2317a">
                           <id root="73f81cac-2d68-4270-8f99-f4d34b0b781e"/>
                           <code code="34077-8" codeSystem="2.16.840.1.113883.6.1" displayName="TERATOGENIC EFFECTS SECTION"/>
                           <text>
                              <paragraph>Corticosteroids are generally teratogenic in laboratory animals when administered systemically at relatively low dosage levels. The more potent corticosteroids have been shown to be teratogenic after dermal application in laboratory animals. There are no adequate and well-controlled studies in pregnant women on teratogenic effects from topically applied corticosteroids. Therefore, topical corticosteroids should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus. Drugs of this class should not be used extensively on pregnant patients, in large amounts, or for prolonged periods of time.</paragraph>
                           </text>
                           <effectiveTime value="20250513"/>
                        </section>
                     </component>
                  </section>
               </component>
               <component>
                  <section ID="ID_964b0acd-24c6-43f4-8287-f26ed4ca74fd">
                     <id root="f046e244-6214-4627-881b-0a8b356eba11"/>
                     <code code="34080-2" codeSystem="2.16.840.1.113883.6.1" displayName="NURSING MOTHERS SECTION"/>
                     <title>Nursing Mothers</title>
                     <text>
                        <paragraph>It is not known whether topical administration of corticosteroids could result in sufficient systemic absorption to produce detectable quantities in breast milk. Systemically administered corticosteroids are secreted into breast milk in quantities <content styleCode="italics">not</content> likely to have a deleterious effect on the infant. Nevertheless, caution should be exercised when topical corticosteroids are administered to a nursing woman.</paragraph>
                     </text>
                     <effectiveTime value="20250513"/>
                  </section>
               </component>
               <component>
                  <section ID="Pediatric">
                     <id root="634c5554-1ae9-4ce1-8082-ef172bb6f744"/>
                     <code code="34081-0" codeSystem="2.16.840.1.113883.6.1" displayName="PEDIATRIC USE SECTION"/>
                     <title>Pediatric Use</title>
                     <text>
                        <paragraph>
                           <content styleCode="italics">Pediatric patients may demonstrate greater susceptibility to topical corticosteroid-induced hypothalamic-pituitary-adrenal (HPA) axis suppression and Cushing's syndrome than mature patients because of a larger skin surface area to body weight ratio.</content>
                        </paragraph>
                        <paragraph>HPA axis suppression, Cushing's syndrome, and intracranial hypertension have been reported in children receiving topical corticosteroids. Manifestations of adrenal suppression in children include linear growth retardation, delayed weight gain, low plasma cortisol levels, and absence of response to ACTH stimulation. Manifestations of intracranial hypertension include bulging fontanelles, headaches, and bilateral papilledema.</paragraph>
                        <paragraph>Administration of topical corticosteroids to children should be limited to the least amount compatible with an effective therapeutic regimen. Chronic corticosteroid therapy may interfere with the growth and development of children.</paragraph>
                     </text>
                     <effectiveTime value="20250513"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="AR">
               <id root="578dd021-24b9-4585-8551-ddefb282bbd9"/>
               <code code="34084-4" codeSystem="2.16.840.1.113883.6.1" displayName="ADVERSE REACTIONS SECTION"/>
               <title>ADVERSE REACTIONS</title>
               <text>
                  <paragraph>The following local adverse reactions are reported infrequently with topical corticosteroids, but may occur more frequently with the use of occlusive dressings. These reactions are listed in an approximate decreasing order of occurrence:</paragraph>
                  <table styleCode="Noautorules" width="85%">
                     <col width="18%"/>
                     <col width="30%"/>
                     <col width="35%"/>
                     <tbody>
                        <tr>
                           <td valign="top">
                              <paragraph>Burning<br/>Itching<br/>Irritation<br/>Dryness<br/>Folliculitis</paragraph>
                           </td>
                           <td valign="top">
                              <paragraph>Hypertrichosis<br/>Acneiform Eruptions<br/>Hypopigmentation<br/>Perioral Dermatitis<br/>Allergic Contact Dermatitis</paragraph>
                           </td>
                           <td valign="top">
                              <paragraph> Maceration of the Skin<br/>Secondary Infection<br/>Skin Atrophy<br/>Striae<br/>Miliaria</paragraph>
                           </td>
                        </tr>
                     </tbody>
                  </table>
               </text>
               <effectiveTime value="20250513"/>
            </section>
         </component>
         <component>
            <section ID="OVERDOSAGE">
               <id root="5d88a482-093f-4fbf-b328-6b5ec91d34a8"/>
               <code code="34088-5" codeSystem="2.16.840.1.113883.6.1" displayName="OVERDOSAGE SECTION"/>
               <title>OVERDOSAGE</title>
               <text>
                  <paragraph>Topically applied corticosteroids can be absorbed in sufficient amounts to produce systemic effects (see <content styleCode="bold">
                        <linkHtml href="#PRECAUTIONS">PRECAUTIONS</linkHtml>
                     </content>).</paragraph>
               </text>
               <effectiveTime value="20250513"/>
            </section>
         </component>
         <component>
            <section ID="DA">
               <id root="2288691a-23f0-44a1-8a25-d6cf2f15d492"/>
               <code code="34068-7" codeSystem="2.16.840.1.113883.6.1" displayName="DOSAGE &amp; ADMINISTRATION SECTION"/>
               <title>DOSAGE AND ADMINISTRATION</title>
               <text>
                  <paragraph>Fluocinonide Cream USP, 0.05%, Fluocinonide Cream USP, 0.05% (Emulsified Base), Fluocinonide Gel USP, 0.05% and Fluocinonide Ointment USP, 0.05% are generally applied to the affected area as a thin film from two to four times daily depending on the severity of the condition.</paragraph>
                  <paragraph>Occlusive dressings may be used for the management of psoriasis or recalcitrant conditions.</paragraph>
                  <paragraph>If an infection develops, the use of occlusive dressings should be discontinued and appropriate antimicrobial therapy instituted.</paragraph>
               </text>
               <effectiveTime value="20250513"/>
            </section>
         </component>
         <component>
            <section ID="HS">
               <id root="d145c316-ffe6-408d-ac6f-908315fd6079"/>
               <code code="34069-5" codeSystem="2.16.840.1.113883.6.1" displayName="HOW SUPPLIED SECTION"/>
               <title>HOW SUPPLIED</title>
               <effectiveTime value="20250513"/>
               <component>
                  <section ID="ID_734f3607-b7a2-4bda-96c2-cab1ec653b33">
                     <id root="2d20001e-fbfd-4a54-94b8-916e94b2648e"/>
                     <code code="44425-7" codeSystem="2.16.840.1.113883.6.1" displayName="STORAGE AND HANDLING SECTION"/>
                     <text>
                        <paragraph>Fluocinonide Ointment USP, 0.05% is supplied in 60g (NDC <content styleCode="bold">68788-8554-6</content>) tubes.</paragraph>
                        <paragraph>
                           <content styleCode="bold">Store at 20°-25°C (68°-77°F).</content> Avoid temperature above 30°C (86°F).</paragraph>
                     </text>
                     <effectiveTime value="20250513"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="ID_ed3cc06d-5663-4af0-a03c-96c2d0e476aa">
               <id root="b84510ca-7e40-48ce-b485-bf7a75fe2485"/>
               <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
               <text>
                  <paragraph>Mfd. by: Taro Pharmaceuticals Inc., Brampton, Ontario, Canada L6T 1C1<br/>Dist. by: <content styleCode="bold">Taro Pharmaceuticals U.S.A., Inc.</content> Hawthorne, NY 10532<br/>Revised: November, 2017<br/>PK-4964-5<br/>77</paragraph>
                  <paragraph>
                     <content styleCode="bold">Relabeled By: Preferred Pharmaceuticals Inc.</content>
                  </paragraph>
               </text>
               <effectiveTime value="20250513"/>
            </section>
         </component>
         <component>
            <section ID="ID_e025f703-68d7-4ba2-b5f0-24a04766e4eb">
               <id root="5164eea6-f340-49cc-a02b-4c073eaea6fc"/>
               <code code="51945-4" codeSystem="2.16.840.1.113883.6.1" displayName="PACKAGE LABEL.PRINCIPAL DISPLAY PANEL"/>
               <title>PRINCIPAL DISPLAY PANEL - 60 g Tube Carton</title>
               <text>
                  <paragraph>
                     <content styleCode="bold">NDC 68788-8554-6</content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold">Fluocinonide</content>
                     <br/>
                     <content styleCode="bold">Ointment USP, 0.05%</content>
                  </paragraph>
                  <paragraph>FOR EXTERNAL USE ONLY. <br/>NOT FOR OPHTHALMIC USE.</paragraph>
                  <paragraph>
                     <content styleCode="bold">Keep this and all medications out of the reach of children.</content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold">60 g</content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold">Rx only</content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold">TARO</content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold">Relabeled By: Preferred Pharmaceuticals Inc.</content>
                  </paragraph>
                  <renderMultiMedia ID="id1088" referencedObject="D6F7209E-3013-44D6-8477-FEF7947AF65B"/>
               </text>
               <effectiveTime value="20250513"/>
               <component>
                  <observationMedia ID="D6F7209E-3013-44D6-8477-FEF7947AF65B">
                     <text>Fluocinonide Ointment USP 0.05% </text>
                     <value mediaType="image/jpeg" xsi:type="ED">
                        <reference value="fluocinonide-05.jpg"/>
                     </value>
                  </observationMedia>
               </component>
            </section>
         </component>
      </structuredBody>
   </component>
</document>